Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Histone deacetylase (HDAC) enzymatic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM). Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM. In the present study, we investigated the preclinical ac...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Santo, Loredana, Hideshima, Teru, Kung, Andrew L., Tseng, Jen-Chieh, Tamang, David, Yang, Min, Jarpe, Matthew, van Duzer, John H., Mazitschek, Ralph, Ogier, Walter C., Cirstea, Diana, Rodig, Scott, Eda, Homare, Scullen, Tyler, Canavese, Miriam, Bradner, James, Anderson, Kenneth C., Jones, Simon S., Raje, Noopur
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Hematology 2012
الموضوعات:
Lymphoid Neoplasia
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3337713/
https://ncbi.nlm.nih.gov/pubmed/22262760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-10-387365
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة